NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/23/2026
Back to search
Official data from USPTO
NAVIGNOSTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NAVIGNOSTICS
ST13
US500000079395780Class
5, 10, 42
Filing
79395780
Registration
7862453
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
07/23/2026
Trademark type
Word
Nice classes
5, 10, 42
Filing date
02/15/2024
Registration date
07/15/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/15/2025
Last transaction
07/23/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
84
Owner location
CH
Examiner
EDWARDS, ALICIA COLLINS
Law office
M60
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Navignostics AG
A. J. (pessoa física)
Representatives
Nicholas D. Wells Legends Law Group, PLLC
Technical classification
Nice Classes
Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Reactants for medical diagnosis; diagnostic preparations for medical purposes; diagnostic reagents for medical or veterinary use in in vitro diagnosis; reactants for medical diagnosisparticularly for usage with spatial single-cell proteomics reagents for diagnostic tests for medical use; diagnostic test reagents for veterinary use; diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations for medical purposes; diagnostic substances for medical use; pharmaceutical productsmedical and veterinary preparationspharmaceutical preparations for use in the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the diagnosis and treatment of cancer; pharmaceutical preparations for the diagnosis of diseases; diagnostic pharmaceutical preparations; pharmaceutical preparations for individual medical diagnosis; medical test kits comprising pharmaceutical preparations for cancer therapy; medical test kits comprising pharmaceutical preparations for use in oncology for cancer screening; medical test kits comprising pharmaceutical preparations for cancer diagnosis; medical test kits comprising pharmaceutical preparations for individual medical diagnosis in the field of protein imaging; diagnostic test kits comprising pathology slides for testing tissue samples; test kits for use in oncology comprising sample tubes for testing tissue samples; diagnostic test kits comprising laboratory equipment for sample preparationprocessing and storage for cancer diagnosis; diagnostic test kits for individual medical diagnosis comprising sample collection equipment for tumour analysis
Class 10
Apparatus for tumour diagnosisImaging Mass Cytometry (IMC) apparatus; medical apparatusspectrometers for machine learning-based spectrum analysis of human blood plasma; Multiplex protein imaging scanners for medical diagnosis; apparatus for clinical diagnosisdigital imaging device; spectrum analysers for use in medical diagnosis; trace material analysers for medical use in diagnosis; apparatus used in implementing diagnosis tests designed to detect abnormal genetic mutations in proteinsspatial proteomics tools; medical test kits for cancer testing; diagnosticexaminationmonitoring equipmentmultiplex protein imaging equipment; medical test kits comprising tissue sampling equipment for the use in oncology for cancer screening; medical test kits for cancer diagnosis; medical test kits comprising tissue analysis tools for individual diagnosis in the field of cancer therapy
Class 42
Scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of proteomics; oncological research; medical research in the field of oncological diagnostics; computer programming for medical data analysis for cancer diagnostics; development of personalized diagnostics products in the nature of data samplingimaging and analysis for cancer treatment; software-as-a-service (SaaS) featuring software for use in cancer diagnosis; platform-as-a-service (PaaS) featuring software for use in cancer diagnosis; software-as-a-service (SaaS) featuring software for cell analysis for use in oncology; platform-as-a-service (PaaS) featuring software for cell analysis for use in oncology; software-as-a-service (SaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; platform-as-a-service (PaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; software-as-a-service (SaaS) featuring software using machine learning in the field of medical diagnosis and researchparticularly for cancer researchtreatment and diagnosis; platform-as-a-service (PaaS) featuring software using machine learning in the field of medical diagnosis and researchparticularly for cancer researchtreatment and diagnosis; computer programming in the field of using machine learning regarding medical diagnosis and researchparticularly for cancer researchtreatment and diagnosis; software as a service (SaaS) featuring software for the analysis of medical dataparticularly for cancer researchtreatment and diagnosis; software-as-a-service (SaaS) featuring software for the analysis of medical dataparticularly for cancer researchtreatment and diagnosis; platform-as-a-service (PaaS) featuring software for the analysis of medical dataparticularly for cancer researchtreatment and diagnosis; software as-a-service (SaaS) featuring software for the digital representation of tumours and tumour features; platform-as-a-service (PaaS) featuring software for the digital representation of tumours and tumour features; software as-a-service (SaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; software as-a-service (SaaS) featuring software for high-resolution digital image representation of digital tumours; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of digital tumours; cancer diagnosis research
Publications
History of USPTO decisions and trademark events.
27 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/02/2026
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/06/2026
XXCR
GENERIC MADRID TRANSACTION CREATED
02/05/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/31/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/15/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/15/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/15/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/15/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
07/15/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/27/2025
PUBO
PUBLISHED FOR OPPOSITION
05/27/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/21/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/28/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/24/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/24/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/24/2025
RFNT
REFUSAL PROCESSED BY IB
10/12/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/23/2024
RFRR
REFUSAL PROCESSED BY MPU
09/23/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/20/2024
CNRT
NON-FINAL ACTION WRITTEN
09/19/2024
DOCK
ASSIGNED TO EXAMINER
09/06/2024
CHLD
CHANGE OF OWNER RECEIVED FROM IB
08/09/2024
MAFR
APPLICATION FILING RECEIPT MAILED
05/22/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/22/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/16/2024
Continuous trademark protection
Get notified about every new filing that threatens NAVIGNOSTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.